Table 2.
Vaccine antigens targeting S. aureus that have been evaluated in human clinical trials.
| Antigen | Description | Sponsor | Clinical study phase | Reference |
|---|---|---|---|---|
| CP8 conjugate CP5 conjugate PVL Hla | CP8 conjugated to rEpA CP5 conjugated to rEpA Panton-Valentine Leukocidin toxoid Alpha hemolysin | GSK | No public disclosure. GSK purchased the Nabi pentavalent S. aureus vaccine (PentaStaph) in 2011 (http://globenewswire.com/news-release/2011/04/27/445328/219830/en/Nabi-Biopharmaceuticals-Completes-Final-PentaStaph-TM-Milestone.html) | |
| SEB | Enterotoxin B | NIAID | (90, 91) | |
| Protein 1 Protein 2 Protein 3 Protein 4 | No public disclosure of the identity of the antigens. | Novartis | 1 | N/A |
| Cbp Clf Fbp Eap | Collagen-binding protein Clumping factor Fibronectin binding protein Extracellular adherence protein | Vaccine Research International | http://www.vri.org.uk/PhaseITrial.pdf | |
| IsdB | Iron surface determinant B | Mercka | (82, 89) | |
| CP5 conjugate | CP5 conjugated to CRM197 | Pfizer | 1, 2 | (92) |
| CP8 conjugate | CP8 conjugated to CRM197 | |||
| Mntc | Manganese transporter C | |||
| ClfA | Clumping factor A | |||
| rAT rLukS-PV | Alpha hemolysin Panton-Valentine Leukocidin toxoid | Uniformed Services University of the Health Sciences | http://www.empr.com/bivalent-s-aureus-vaccine-demonstrates-good-immunogenicity-and-neutralizing-activity/article/314713/ | |
| CP8 conjugate | CP8 conjugated to rEpA | Nabia | 1, 2, 3 | (93, 94) |
| CP5 conjugate | CP5 conjugated to rEpA | |||
| CP336 conjugate | CP336 conjugated to rEpA |
aDevelopment terminated.
CP, capsular polysaccharide; rEpA, recombinant P. aeruginosa exoprotein A; CRM197, cross-reactive material 197; a non-toxic recombinant variant of diphtheria toxin (Corynebacterium diphtheriae).